Pioglitazone: Revision history


For any version listed below, click on its date to view it. For more help, see Help:Page history and Help:Edit summary. (cur) = difference from current version, (prev) = difference from preceding version, m = minor edit, → = section edit, ← = automatic edit summary

(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)

9 March 2024

9 February 2024

19 January 2024

  • curprev 14:0014:00, 19 January 2024Maxim Masiutin talk contribs 28,246 bytes +61 Alter: first1, last11, title. Add: pmid, s2cid. Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors. undo

20 December 2023

11 December 2023

10 December 2023

9 November 2023

4 September 2023

18 April 2023

15 February 2023

8 January 2023

9 December 2022

7 November 2022

24 July 2022

9 July 2022

1 July 2022

28 June 2022

27 June 2022

  • curprev 06:3006:30, 27 June 2022Boghog talk contribs 27,434 bytes −460 consistent citation formatting undo
  • curprev 05:0905:09, 27 June 2022ThePhysiolosopher talk contribs 27,894 bytes +1,830 →‎Medical uses: Added conclusions of Cambpell Collaboration Systematic Review Campbell Systematic Review Ipsen EØ, Madsen KS, Chi Y, Pedersen-Bjergaard U, Richter B, Metzendorf M-I, Hemmingsen B. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2020, Issue 11. Art. No.: CD013516. DOI: 10.1002/14651858.CD013516.pub2. undo Tag: Visual edit

6 March 2022

5 January 2022

15 December 2021

29 November 2021

1 November 2021

10 October 2021

14 September 2021

8 September 2021

25 August 2021

22 August 2021

19 August 2021

10 August 2021

5 July 2021

3 July 2021

3 May 2021

26 April 2021

24 April 2021

24 March 2021

28 January 2021

14 January 2021

(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)